Organisation paid for research Program year 2024 Source: CMS Open Payments

Ararat Research Center

Neither a doctor nor a teaching hospital

Research payments

$48,430

44 payments

Through program year 2024, Ararat Research Center is reported as receiving $48,430 in research payments, across 44 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $3,444 2
2021 Research $10,482 3
2020 Research $7,081 10
2019 Research $27,423 29

Breakdown

Who paid Research payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $48,430 44 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects $18,760 9 payments
  2. A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects $15,088 6 payments
  3. A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na HIV-1 Infected Subjects $9,982 2 payments
  4. A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1 Infected Subjects $3,444 2 payments
  5. A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects $656 24 payments
  6. A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record